Pharmaceutical

CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio

CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.

Aug 2, 2023 - 20:00
CS Pharmaceuticals snaps up AxeroVision to shore up ophthalmology portfolio
CSP will revive the development of AXR-270, a drug that previously demonstrated positive results for DED in 2021.
Read the original article

Tags:

Previous Article

STAT+: Pharmalittle: House Republicans and Democrats duel over drug shortages; F...

Next Article

Atantares raises $13.9m in pre-Series A funding to develop molecular chips

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: AstraZeneca shares fall after lung cancer drug underwhelms in trial

STAT+: AstraZeneca shares fall after lung cancer drug u...

Jul 4, 2023

STAT+: ‘True disruption’: Mark Cuban’s company will sell brand-name diabetes medicines from J&J

STAT+: ‘True disruption’: Mark Cuban’s company will sel...

Apr 5, 2023

Listen: The plight of the VC, Gilead’s latest setback, & more M&A

Listen: The plight of the VC, Gilead’s latest setback, ...

Jan 26, 2024